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Abstract
Information about the epidemiology of resistance in Streptococcus pneumoniae within southern and eastern countries of the Mediterra-
nean region is incomplete, as reports have been sporadic and difﬁcult to compare. Over a 36-month period, from 2003 to 2005, the
ARMed project collected 1298 susceptibility test results of invasive isolates of S. pneumoniae from blood and spinal ﬂuid cultures rou-
tinely processed within 59 participating laboratories situated in Algeria, Cyprus, Egypt, Jordan, Lebanon, Malta, Morocco, Tunisia and
Turkey. Overall, 26% (335) of isolates were reported as non-susceptible to penicillin, with the highest proportions being reported from
Algeria (44%) and Lebanon (40%). During the same time period, the highest proportions of pneumococci that were not susceptible to
erythromycin were reported from Malta (46%) and Tunisia (39%). Proportions of dual non-susceptibility in excess of 5% were found in
laboratories in Algeria, Tunisia, Lebanon, Jordan and Turkey. ARMed data on the antimicrobial resistance epidemiology of S. pneumoniae
in the southern and eastern Mediterranean region provided evidence of high rates of resistance, especially to penicillin. This evidence
calls for a greater focus on the identiﬁcation of relevant drivers of resistance and on the implemention of effective practices in order to
address the problem of resistence.
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Introduction
Streptococcus pneumoniae accounts for considerable mortality
and morbidity as a result of community-acquired infections
including meningitis, pneumonia, sepsis and otitis media [1].
In developing countries, pneumococcal infections have been
estimated to account for more then a million deaths annually
in children aged <5 years [2]. During the past decades, pneu-
mococci have developed antimicrobial resistance to various
antibiotic classes, including penicillins, macrolides and cepha-
losporins [3]. This, in turn, has signiﬁcant repercussions on
the treatment of the pneumococcal infections [4,5].
For this reason, comprehensive knowledge of the epidemi-
ology of pneumococcal resistance is vital to monitor chang-
ing trends and attempt interventions to halt these trends.
Consequently, several surveillance networks have been
established worldwide, especially in the USA [6], Latin Amer-
ica [7] and Europe [8]. These networks have identiﬁed geo-
graphical variations in resistance patterns among
pneumococci. However, equivalent data about the situation
in the southern and eastern Mediterranean region have been
sparse. In addition to being few in number, studies have
often been unrelated, using different methodologies and
specimen types; as a result, they are difﬁcult to compare [9].
This lacuna has been addressed by the Antibiotic Resis-
tance Surveillance & Control in the Mediterranean Region
(ARMed) project (http://www.slh.gov.mt/armed) [10]. During
a 3-year period, this European Union-funded study has docu-
mented the prevalence of antibiotic resistance in several key
pathogens in nine southern and eastern Mediterranean coun-
tries. This publication focuses on the work undertaken in
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participating laboratories to evaluate the epidemiology of
resistance in S. pneumoniae in these countries.
Materials and Methods
ARMed collected antimicrobial susceptibility test results for
S. pneumoniae strains isolated by the participating laborato-
ries from routine blood cultures and cerebrospinal ﬂuids and
conﬁrmed by an optochin test. The database included only
the ﬁrst isolate causing an infection in any individual patient
within 1 year. ARMed laboratories screened invasive S. pneu-
moniae isolates for oxacillin resistance (using oxacillin disks
of 1 or 5 lg, depending on the guidelines used). When
found, non-susceptibility was conﬁrmed by determination of
the MIC using the Etest (AB Biodisk, Solna, Sweden). Testing
of erythromycin susceptibility was also mandatory. ARMed
protocols are accessible at the ARMed website (http://
www.slh.gov.mt/armed/earss.asp). The website also includes
an interactive function where maps, tables or graphs for spe-
ciﬁc antibiotic–pathogen combinations for any of the partici-
pating countries can be generated, as speciﬁed by the user.
All antimicrobial susceptibility testing was performed by
the individual laboratories, who interpreted the results
according to their own guidelines, which in 70% of laborato-
ries were based on CLSI guidelines and breakpoints. The
other laboratories followed the French guidelines of the
Comite´ de l’Antibiogramme de la Socie´te´ Franc¸aise de Mi-
crobiologie.
External quality assessment (EQA) results
To ensure comparability of test results, two quality assur-
ance exercises were performed in 2003 and 2004. One of
the S. pneumoniae strains sent to study participants in 2003
was erythromycin-resistant and was correctly identiﬁed by
92% of laboratories. The other S. pneumoniae strain was
intermediately resistant to penicillin, and was correctly iden-
tiﬁed by 56% of the laboratories. However, when the desig-
nated interpretation for oxacillin susceptibility of this
S. pneumoniae strain was changed from ‘intermediate only’ to
‘intermediate and resistant’ by the EQA organizers, this
resulted in an overall concordance of 88% in the ARMed
participating laboratories. The S. pneumoniae strain sent to
study participants in 2004 had a mutation in the parC coding
region that confers reduced susceptibility to ﬂuoroquinol-
ones. This strain was also non-susceptible to penicillin and
resistant to erythromycin, and this was correctly detected by
82% and 81% of the laboratories, respectively.
Country-speciﬁc trend analysis was performed using the
Cochrane–Armitage test. Countries were required to report
at least 20 isolates per year, for all 3 years, to be included in
the trend analysis.
Results
In total, 1298 invasive S. pneumoniae isolates were reported
to ARMed from 2003 to 2005. Overall, 25% of these isolates
were reported as penicillin-non-susceptible S. pneumoniae
(PNSP), i.e. either intermediate or resistant to penicillin. In
2005, the lowest proportions of PNSP isolates were found in
Malta (15%, n = 13) and Morocco (17%, n = 42). The highest
proportions of PNSP isolates were reported from Algeria
(44%, n = 71) and Lebanon (40%, n = 10) (Table 1). From
2003 to 2005, a signiﬁcant decrease in PNSP isolates was
observed in Egypt (from 39% to 17%; p 0.002), and a signiﬁ-
cant increase in PNSP isolates was observed in Turkey (from
12.8% to 24.3%; p 0.03).
During the same time period, 1172 S. pneumoniae isolates
(90% of the total) were tested for erythromycin susceptibil-
ity. In 2005, the lowest proportions of erythromycin-non-
susceptible S. pneumoniae isolates were found in Turkey
(10%, n = 98) and Morocco (12%, n = 41). The highest pro-
portions of erythromycin-non-susceptible S. pneumoniae iso-
lates were reported from Malta (46%, n = 13) and Tunisia
(39%, n = 33). From 2003 to 2005, no signiﬁcant decrease
or increase was observed in any of the countries participat-
ing in the project.
In 2005, the highest proportions of dual non-susceptibility
(deﬁned as penicillin intermediate or full resistance, together
with erythromycin resistance) were reported from Tunisia
(24%, n = 33) and Lebanon (20%, n = 10), with the lowest
proportions being found in Egypt (3%, n = 121) and Malta
(0%, n = 13).
Fig. 1 shows the overall results of single erythromycin, sin-
gle penicillin and dual non-susceptibility by country for the
entire ARMed data collection period (2003–2005). No signiﬁ-
cant differences over time were observed for single penicillin
or single erythromycin resistance, except in Turkey, where a
signiﬁcant decrease was observed for single erythromycin
resistance (p 0.04). A signiﬁcant increase in combined resis-
tance to penicillin and erythromycin (dual non-susceptibility)
was reported by Turkey, from 3% to 10% (p 0.04), which
seemed to replace single erythromycin resistance. A signiﬁ-
cant decrease in dual non-susceptibility was observed in
Egypt, from 21% to 3% between 2003 and 2005 (p 0.001).
The distribution of penicillin and erythromycin resistance
was also considered by age in two countries in the southern
Mediterranean region (Algeria and Malta) and in another two
in the eastern region (Egypt and Turkey). In Algeria, the
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highest proportion of resistant pneumococci, particularly
those exhibiting dual non-susceptibility, was seen in individu-
als aged <4 years (Fig. 2). However, this was not the case in
the other countries, where resistant isolates were spread
throughout all age groups, and the highest resistance per-
centages were found in older children and young adults.
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FIG. 1. Single erythromycin, single penicillin and dual resistance (intermediate or resistant) proportions found within the indicated number of
isolates, tested for both antibiotics during the 3-year study period by laboratories in the ARMed participating countries: Cyprus (CY), Algeria
(DZ), Egypt (EG), Jordan (JO), Lebanon (LB), Morocco (MA), Malta (MT), Tunisia (TN) and Turkey (TR).
TABLE 1. Number of invasive Streptococcus pneumoniae isolates, and the proportion of penicillin non-susceptible
S. pneumoniae (PNSP), erythromycin non-susceptible S. pneumoniae (ENSP) and dual non-susceptible (DUAL) strains,
including 95% CIs, as reported by country per year
Country Year No. tested
for penicillin
No. tested for
erythromycin
PNSP
(95%
CI) (%)
ENSP
(95%
CI) (%)
DUAL
(95%
CI) (%)
Algeria 2003 32 27 41 (24–59) 19 (7–39) 11 (3–30)
2004 113 93 40 (31–49) 22 (14–31) 11 (6–19)
2005 71 61 44 (32–56) 16 (9–29) 11 (5–23)
Overall 216 181 41 (35–48) 19 (14–26) 11 (7–17)
Cyprus 2003 3 3 0 (0–69) 33 (2–87) 0 (0–69)
2004 7 7 14 (1–58) 0 (0–44) 0 (0–44)
2005 16 16 19 (5–46) 13 (2–40) 13 (2–40)
Overall 26 26 15 (5–36) 12 (3–31) 8 (1–27)
Egypt 2003 49 28 39 (26–54) 32 (17–52) 21 (9–41)
2004 175 168 27 (21–34) 22 (16–29) 4 (2–9)
2005 123 121 17 (11–25) 22 (15–31) 3 (1–8)
Overall 347 317 25 (21–30) 23 (19–28) 5 (3–8)
Jordan 2003 23 16 30 (14–53) 31 (12–59) 25 (8–53)
2004 18 15 33 (14–59) 13 (2–42) 13 (2–42)
2005 16 15 38 (16–64) 27 (9–55) 13 (2–42)
Overall 57 46 33 (22–47) 24 (13–39) 17 (8–32)
Lebanon 2003 4 4 50 (9–91) 25 (1–78) 25 (1–78)
2004 2 2 100 (20–95) 50 (3–97) 50 (3–97)
2005 10 10 40 (14–73) 20 (4–56) 20 (4–56)
Overall 16 16 50 (26–74) 25 (8–53) 25 (8–53)
Morocco 2003 38 21 26 (14–43) 5 (0–26) 0 (0–19)
2004 30 29 3 (0–19) 17 (7–36) 0 (0–15)
2005 42 41 17 (8–32) 12 (5–27) 5 (1–18)
Overall 110 91 16 (10–25) 12 (6–21) 2 (0–8)
Malta 2003 9 8 0 (0–37) 38 (10–74) 0 (0–40)
2004 18 16 0 (0–22) 25 (8–53) 0 (0–24)
2005 13 13 15 (3–46) 46 (20–74) 0 (0–28)
Overall 40 37 5 (1–18) 35 (21–53) 0 (0–12)
Tunisia 2003 38 37 13 (5–29) 27 (14–44) 11 (4–26)
2004 46 46 44 (29–59) 33 (20–48) 24 (13–39)
2005 33 33 27 (14–46) 39 (23–58) 24 (12–43)
Overall 117 116 29 (21–38) 33 (25–42) 20 (13–28)
Turkey 2003 117 105 13 (8–21) 7 (3–14) 3 (1–9)
2004 149 139 23 (17–31) 9 (5–16) 7 (4–13)
2005 103 98 24 (17–34) 10 (5–18) 10 (5–18)
Overall 369 342 20 (16–25) 9 (6–12) 7 (4–10)
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Discussion
ARMed data have arguably provided the ﬁrst comprehensive
pan-regional picture of resistance in S. pneumoniae within the
southern and eastern Mediterranean region. The results
obtained indicate a very heterogeneous situation, which var-
ies signiﬁcantly from country to country. This is evident par-
ticularly in the case of full penicillin resistance, where the
greatest difference was ten-fold; the countries with the high-
est levels of full resistance were in the Middle Eastern
region. On the other hand, in the case of macrolide resis-
tance, the difference was less than three-fold between the
countries with the highest and the lowest proportions. Fur-
thermore, it is difﬁcult to acquire evidence of regional clus-
tering for increased erythromycin resistance, which is made
evident by the remarkably different proportions observed in
Tunisia and Morocco, two neighbouring north African coun-
tries. This would suggest that several independent clones are
distributed in the countries of the region, each with its own
resistance proﬁle, possibly imported from other countries.
The ARMed results correlate reasonably well with spo-
radic results from previous isolated studies in the countries
of the region. An Egyptian study reported 49% of the pneu-
mococcal isolates tested to be non-susceptible to penicillin
[2], whereas 32% of the isolates in ﬁve Turkish cities were
found to be non-susceptible to penicillins, with even higher
rates of non-susceptibility being found to macrolides [11].
Reports from North Africa have identiﬁed rates of non-sus-
ceptibility to penicillin of 34.6% in Algeria [12], 9.2% in Mor-
occo [13] and 35% in Tunisia [14]. In most instances, these
results are somewhat higher than those identiﬁed by ARMed.
One possible explanation for this discrepancy may be the
varying methodologies of these studies, especially the use of
isolates obtained from respiratory tract specimens. Signiﬁcant
differences in antimicrobial susceptibility between isolates of
S. pneumoniae taken from the respiratory tract and those
from blood culture have been identiﬁed [15]. The advantage
of using only blood culture and spinal ﬂuid isolates is that,
although they represent a smaller subset of clinical infections,
they are all fully relevant from a clinical viewpoint, as they
represent true infection. This is especially the case with
S. pneumoniae, where septicaemia and meningitis are the
manifestations with the highest morbidity and mortality.
These results add further weight to previous suggestions
that the Mediterranean region is a high-prevalence area for
pneumococcal resistance. Between 1998 and 2000, penicillin
resistance above 10%, according to the Alexander project,
was (with the exception of Ireland) reported only by Euro-
pean countries of the Mediterranean region [16]. This was
subsequently conﬁrmed by the more comprehensive Euro-
pean Antimicrobial Resistance Surveillance System (EARSS)
network, with penicillin non-susceptibility rates above 20%
being reported from Spain, Israel, Hungary, Slovenia, Portugal
and Croatia—all, but one, being southern European coun-
tries [8].
The results from the southern and eastern Mediterranean
region, however, reveal a number of crucial differences from
their northern counterparts. Seasonal variation in PNSP iso-
lates has also been reported from Europe [17]. Similar ﬁnd-
ings were not apparent from the present data, although a
degree of autocorrelation, suggestive of seasonality, was evi-
dent in the total monthly count of S. pneumoniae isolates.
However, as a result of the restricted number of isolates
and the differences in geographical location, it was not possi-
ble to reach ﬁrm conclusions. Additionally, in Europe, penicil-
lin resistance tends to be substantially lower than macrolide
resistance, whereas many of the countries participating in
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FIG. 2. Distribution of penicillin and erythromycin non-susceptibility by age, for the 3-year study period. Algeria (DZ), Egypt (EG), Malta (MT)
and Turkey (TR) were the only countries that supplied data on age.
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ARMed, especially those in the Middle Eastern region,
reported predominantly penicillin non-susceptibility as the
major resistance trait.
This is not to say that erythromycin resistance is not a
relevant regional concern. In many of the countries, substan-
tial levels of resistance to macrolides were still observed, as
well as dual non-susceptibility to erythromycin and penicillin.
Furthermore, distribution among the age groups shows
interesting variations. In many European countries, macro-
lide-resistant pneumococci are predominantly isolated from
infants and the elderly [17,18]. Erythromycin resistance has
been postulated to arise following heavy antibiotic use, which
would explain the higher incidence in children, who are often
treated with this antimicrobial for upper respiratory tract
infections [19]. However, in Malta and Egypt, macrolide-
resistant isolates tended to be more common in older age
groups. This could imply a heavy use of this antibiotic class
across all ages, and suggests generally inadequate antibiotic
stewardship at the community level. Descriptions of over-
the-counter dispensing of these antimicrobials have in fact
come from Malta and would support this hypothesis [20].
Whatever the cause, the substantial resistance rates are a
major cause for alarm. Resistance in S. pneumoniae has been
linked to treatment failure and to subsequent spread of
resistant clones [21], particularly in the case of erythromycin
resistance, which tends to be solid and signiﬁcant [22].
The link between antibiotic consumption in the commu-
nity and resistance has been made, not only for macrolides.
Bronzwaer et al. [23] showed a statistically signiﬁcant corre-
lation between the level of b-lactam antibiotic sales to outpa-
tients in 11 European countries and penicillin resistance in
invasive pneumococci. They also suggest a direct relationship
between resistance and non-compliance rates of antibiotic
use.
Goldstein suggests that various other antimicrobial clas-
ses may also be responsible, including cephalosporins and
co-trimoxazole [24]. It would therefore appear that better
practice concerning antibiotic use in the ambulatory-care
setting is critical if the current situation is to be reversed.
There are several accounts of situations in which penicillin
resistance in pneumococci has been reversed following
improved prescribing policies [25]. Furthermore, the poten-
tial beneﬁt of the pneumococcal vaccine to reduce the
prevalence of resistant strains has also been elucidated
[26]. The introduction of the seven-valent pneumococcal
conjugate vaccine in Spain and other European countries
has been linked to a change in the epidemiology of invasive
pulmonary disease and a decrease in antibiotic resistance
[27]. These are approaches that the countries of the
southern and eastern Mediterranean region may wish to
evaluate in order to address the epidemiological situation
identiﬁed by the ARMed results.
To obtain its basic dataset, the ARMed project adopted
the well-established method of ‘sentinel’ laboratories [28].
Sentinel surveillance is especially useful in the case of devel-
oping countries, where surveillance infrastructure and the
funds required to set it up are often lacking. However, like
other similar surveillance studies, the ARMed project was
limited by its dependence on the accuracy and validity of the
reports from individual participating laboratories. Although
laboratories were requested to test each strain for penicillin
and erythromycin sensitivity, this was not always done.
It will be appreciated that any study that relies on rou-
tinely generated susceptibility data will involve a degree of
non-compliance, especially in laboratories in developing
countries. Although all strains that were not tested simulta-
neously for both penicillin and erythromycin could have been
eliminated, this would have reduced the number of strains
and hence the power of the study. Nevertheless, the ARMed
data are not compromised to any appreciable extent. On the
contrary, the use of standard methodologies and antimicro-
bial panels by all laboratories, the satisfactory results
obtained from the EQA exercise and, above all, the number
of isolates tested substantiate the validity of the ARMed
results.
In conclusion, ARMed data on the antimicrobial resistance
epidemiology of S. pneumoniae in the southern and eastern
Mediterranean region provide evidence of high rates of resis-
tance, especially to penicillin. These ﬁndings make clear the
need for investigation of possible drivers behind the resis-
tance trends, as well as the need for strengthening of both
national and international initiatives aimed at improving sur-
veillance of antimicrobial resistance in the region.
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